GlassScriptPhysician profile
Steven N Hochwald
NPI 1912943010
$11,858.43
in general payments reported to CMS, 2019-2025
43 companies · $2,234 in 2025
The $2,234 reported for 2025 was more than what 83% of Surgical Oncology providers received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,813 · 2020: $150 · 2021: $29.76 · 2022: $124 · 2023: $576 · 2024: $931 · 2025: $2,234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,904 · Travel and Lodging: $837.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,904.14 |
| Travel and Lodging | $837.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $7,630.29 | 2019 | |
| Histosonics, INC. | $1,062.41 | 2025 | |
| Janssen Biotech, INC. | $284.16 | 2022-2025 | Rybrevant, Carvykti, Darzalex |
| Daiichi Sankyo INC. | $281.38 | 2023-2025 | Enhertu |
| Ipsen Biopharmaceuticals, INC | $264.81 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $178.25 | 2022-2025 | Keytruda, Lynparza |
| Hologic Sales and Service, LLC | $159.53 | 2024 | Trident Specimen Radiography System |
| Taiho Oncology, INC. | $145.06 | 2023-2025 | |
| Incyte Corporation | $127.90 | 2023-2025 | Monjuvi, Pemazyre, Jakafi |
| Bayer Healthcare Pharmaceuticals INC. | $124.99 | 2024 | |
| Genentech USA, INC. | $124.46 | 2022-2025 | Polivy, Venclexta, Lunsumio |
| Emd Serono, INC. | $105.40 | 2023-2025 | Bavencio |
| Astrazeneca Pharmaceuticals LP | $105.23 | 2024-2025 | Lynparza, Imfinzi |
| Ethicon US, LLC | $97.80 | 2019-2021 | |
| Eisai INC. | $94.02 | 2024-2025 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $93.69 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $74.06 | 2022-2025 | Fruzaqla, Ninlaro |
| Pfizer INC. | $73.41 | 2024-2025 | |
| Springworks Therapeutics, INC. | $67.13 | 2024-2025 | Ogsiveo |
| Aveo Pharmaceuticals, INC. | $62.19 | 2025 | |
| Servier Pharmaceuticals LLC | $59.32 | 2023-2025 | |
| Adaptive Biotechnologies Corporation | $55.20 | 2023-2025 | Clonoseq |
| Exelixis INC. | $46.32 | 2022-2023 | Cabometyx |
| Astellas Pharma US INC | $43.39 | 2025 | Xospata |
| Deciphera Pharmaceuticals INC. | $41.40 | 2023 | Qinlock |
| Beone Medicines USA, INC. | $40.75 | 2025 | Tevimbra, Brukinsa |
| Pharmacyclics LLC, An Abbvie Company | $39.80 | 2023 | Epkinly, Imbruvica |
| Aimmune Therapeutics, INC. | $38.78 | 2025 | Zenpep |
| Alexion Pharmaceuticals, INC. | $34.77 | 2024 | Ultomiris |
| Stemline Therapeutics INC. | $34.01 | 2024-2025 | Orserdu |
| Genzyme Corporation | $33.90 | 2024 | |
| Abbvie INC. | $33.87 | 2025 | |
| Sumitomo Pharma America, INC. | $23.36 | 2025 | Orgovyx |
| Agios Pharmaceuticals, INC. | $22.74 | 2024 | |
| Recordati_rare_diseases_inc. | $20.32 | 2024 | Sylvant |
| Myriad Genetic Laboratories, INC. | $18.80 | 2023 | Myrisk |
| Jazz Pharmaceuticals INC. | $18.40 | 2025 | |
| Kite Pharma, INC. | $18.21 | 2023 | Yescarta |
| Lilly USA, LLC | $18.19 | 2025 | Verzenio, Jaypirca, Retevmo |
| Amgen INC. | $16.52 | 2023 | Lumakras |
| Medtronic, INC. | $15.67 | 2025 | Signia |
| Pharmaand Gmbh | $14.27 | 2025 | Rubraca |
| Tolmar, INC. | $14.27 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Hochwald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.